General Low discontinuation rates confirm manageable safety of iza-brenBy Healthcare Propulsion StaffSeptember 12, 20260 An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated…